SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001651308-23-000025
Filing Date
2023-01-31
Accepted
2023-01-31 16:26:44
Documents
12
Period of Report
2023-01-30
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K bgne-20230130.htm   iXBRL 8-K 44972
  Complete submission text file 0001651308-23-000025.txt   180816

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT bgne-20230130.xsd EX-101.SCH 1899
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT bgne-20230130_lab.xml EX-101.LAB 23748
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT bgne-20230130_pre.xml EX-101.PRE 12482
6 EXTRACTED XBRL INSTANCE DOCUMENT bgne-20230130_htm.xml XML 11051
Mailing Address C/O MOURANT GOVERNANCE SERVICES (CAYMAN) 94 SOLARIS AVENUE, CAMANA BAY GRAND CAYMAN E9 KY1-1108
Business Address C/O MOURANT GOVERNANCE SERVICES (CAYMAN) 94 SOLARIS AVENUE, CAMANA BAY GRAND CAYMAN E9 KY1-1108 13459494123
BeiGene, Ltd. (Filer) CIK: 0001651308 (see all company filings)

IRS No.: 981209416 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37686 | Film No.: 23572899
SIC: 2834 Pharmaceutical Preparations